ドゥームロード

About NCVC About NCVC About NCVC TOP The Center's Mission Organization History of the NCVC Location News Releases Close Hospital Hospital Hospital TOP About the Hospital The Group of Treatment Close Research Institute Research Institute Research Institute TOP About the Research Institute Departments Office for the Promotion of Diversity and Inclusion Research Institute and Open Innovation Center Brochure Close Open Innovation Center Open Innovation Center Open Innovation Center TOP Research Institute and Open Innovation Center Brochure Close Pamphlet National Cerebral and CardiovascularCenter Hospital Res. Inst. OICOpen Innovation Center Access Background White Black Japanese Access Menu National Cerebral and Cardiovascular Center TOP About NCVC News Releases Researchers revealed the benefits and risks of continuing oral anticoagulation therapy after catheter ablation for atrial fibrillation according to the thromboembolic risk. About NCVC Researchers revealed the benefits and risks of continuing oral anticoagulation therapy after catheter ablation for atrial fibrillation according to the thromboembolic risk.  Researchers in National Cerebral and Cardiovascular Center have just published the study “Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks” online in the international academic journal, European Heart Journal on 19th December 2023. https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehad798 Catheter ablation for atrial fibrillation (AF) has become a common procedure worldwide. An expert consensus statement on catheter ablation for AF recommends the continuation of oral anticoagulants after the post-ablation period should be based on the patient’s risk of stroke and preferences; however, few recent large studies are focusing on the risks and benefits of continuing oral anticoagulation therapy after catheter ablation for AF.A team of researchers, led by Dr. Yoshitaka Iwanaga, performed a nationwide cohort study using administrative data that covers almost all healthcare insurance in Japan and analyzed the rate of continuing oral anticoagulants after catheter ablation and the occurrence of thromboembolic and major bleeding events related to the oral anticoagulation therapy according to the thromboembolic risk. At 6 months and 1 year after the catheter ablation, 71% and 53% of the patients continued oral anticoagulation therapy, respectively, and its rate was higher in the higher CHADS2 score group than in the lower CHADS2 score group (Figure). Continuing oral anticoagulation therapy after 6 months postoperatively for catheter ablation was associated with a higher risk of major in patients with a CHADS2 score of ≤ 2 and was associated with a lower risk of thromboembolism in patients with a CHADS2 score of ≥ 3. “A substantial number of patients continued their oral anticoagulation therapy after catheter ablation for AF in Japan, but our results support the discontinuation strategy of oral anticoagulants after catheter ablation in patients with a lower thromboembolic risk.” – Dr. Koshiro Kanaoka This research could provide critical insights for healthcare providers when considering whether to continue oral anticoagulant therapy after catheter ablation for AF.Figure. Continuation of oral anticoagulation therapy after a first-time catheter ablation and the benefits and risks of continuing oral anticoagulation therapy after catheter ablation for AF.*CHADS2 score: Score estimating the risk of stroke in patients with AF (min: 0 – max: 6 points).last updated：2023/12/20 (Corporate number:3120905003033) 6-1 Kishibe-Shimmachi, Suita, Osaka, 564-8565, Japan TEL：81-6-6170-1070 Access Copyright © National Cerebral and Cardiovascular Center All rights reserved. Site setting Font-size Normal Large Background White Black Japanese English